

# Performance

---

2021 was a year in which we set all-time highs in several financial categories — including Revenue and Adjusted Diluted EPS.

Learn more about our performance on our [Investor site](#).

# Financial Performance

Three-year summary for the years ended December 31

Millions (Except Per Common Share Data)				% Change	
	2021	2020	2019	21/20	20/19
Revenues	\$ 81,288	\$ 41,651	\$ 40,905	95	2
Reported net income <sup>(a)</sup>	\$ 21,979	\$ 9,159	\$ 16,026	*	(43)
Reported diluted EPS <sup>(a)</sup>	\$ 3.85	\$ 1.63	\$ 2.82	*	(42)
Adjusted income <sup>(b)</sup>	\$ 25,236	\$ 12,727	\$ 11,056	98	15
Adjusted diluted EPS <sup>(b)</sup>	\$ 4.42	\$ 2.26	\$ 1.95	96	16
Net cash provided by operating activities	\$ 32,580	\$ 14,403	\$ 12,588	*	14
Cash dividends paid	\$ 8,729	\$ 8,440	\$ 8,043	3	5

\* Indicates calculation not meaningful or result is equal to or greater than 100%.

<sup>(a)</sup> Reported net income is defined as *Net income attributable to Pfizer Inc. common shareholders* in accordance with U.S. GAAP. Reported diluted earnings per share (EPS) is defined as *EPS attributable to Pfizer Inc. common shareholders—diluted* in accordance with U.S. GAAP.

<sup>(b)</sup> Adjusted income and Adjusted diluted EPS are defined as U.S. GAAP *Net income attributable to Pfizer Inc. common shareholders* and reported *EPS attributable to Pfizer Inc. common shareholders—diluted* before the impact of purchase accounting for acquisitions, acquisition-related items, discontinued operations and certain significant items. The Adjusted income and Adjusted diluted EPS measures are not, and should not be viewed as, substitutes for U.S. GAAP net income and diluted EPS, have no standardized meaning prescribed by U.S. GAAP and may not be comparable to the calculation of similar measures of other companies. See the *Non-GAAP Financial Measure: Adjusted Income* section of [Management's Discussion and Analysis of Financial Condition and Results of Operations](#) in Pfizer's 2021 Annual Report on Form 10-K for an explanation of how management uses these non-GAAP measures, reconciliations to the most directly comparable GAAP measures and additional information.

Detailed information on our financial and operational performance can be found in our 2021 Annual Report on Form 10-K.

# Top 10 Medicines and Vaccines

Take a look at our breakdown of the top medicines and vaccines by revenue from 2021.

● **\$36,781 million**

Comirnaty®

● **\$5,970 million**

Eliquis® (apixaban)

● **\$5,437 million**

Ibrance® (palbociclib)

● **\$5,272 million**

Pevnar Family®

● **\$2,455 million**

Xeljanz® (tofacitinib)

● **\$2,015 million**

Vyndaqel®/Vyndamax™ (tafamidis)

● **\$1,185 million**

Enbrel® (etanercept)

● **\$1,185 million**


Xtandi® (enzalutamide)

● **\$1,002 million**

Inlyta® (axitinib)

● **\$683 million**

Sulperazon® (sulbactam sodium/cefoperazone sodium)



View the interactive graph on the [Annual Review site](#).